deuterium has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aichholz, R; Blasco, F; Manley, PW; Mestan, J | 1 |
| Beijnen, JH; Groenland, SL; Huitema, ADR; Lucas, L; Nuijen, B; Roosendaal, J; Rosing, H; Steeghs, N; Venekamp, N | 1 |
1 trial(s) available for deuterium and imatinib mesylate
| Article | Year |
|---|---|
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Chromatography, Liquid; Deuterium; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isotope Labeling; Male; Middle Aged; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2020 |
1 other study(ies) available for deuterium and imatinib mesylate
| Article | Year |
|---|---|
The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Biotransformation; Deuterium; Humans; Hydrogen; Imatinib Mesylate; Male; Microsomes, Liver; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats | 2013 |